{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-014630","form_type":"8-K","ticker":null,"cik":"0001061027","company_name":"Viracta Therapeutics, Inc.","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.839583+00:00","generated_at":"2026-05-27T02:20:07.046915+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Viracta Therapeutics terminates employees, wind down operations; all directors resign","bullets":["Board approved workforce reduction effective Feb 5, 2025; expects ~$0.1M in severance and related costs.","All directors (Pomerantz, Borellini, Darcy, Royston, Rothera) resigned; CEO Rothera, CFO Faerm, CMO Cohen cease officer roles.","Craig Jalbert appointed sole director, CEO, President, CFO, Treasurer and Corporate Secretary; compensated $50K/yr for 3 years.","Company exploring strategic alternatives for its virus-associated cancer development programs.","Wind down follows clinical-stage operations; stock ticker VIRX."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-014630","json":"https://secwatch.observer/filing/0000950170-25-014630.json","markdown":"https://secwatch.observer/filing/0000950170-25-014630.md","text":"https://secwatch.observer/filing/0000950170-25-014630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/virx-20250203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:20:07.046915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"235f7f22c3","claim":"Mark Rothera departed as President and Chief Executive Officer at Viracta Therapeutics, Inc..","evidence_excerpt":"it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"350c5e1b8b","claim":"Craig R. Jalbert was appointed as Director at Viracta Therapeutics, Inc..","evidence_excerpt":"the Board appointed Craig R. Jalbert, age 63, as the Company's Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary, and sole member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4780db845c","claim":"Michael Faerm departed as Chief Financial Officer at Viracta Therapeutics, Inc..","evidence_excerpt":"it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"5072a9c558","claim":"Roger Pomerantz resigned as Director at Viracta Therapeutics, Inc..","evidence_excerpt":"Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"802dbf9ff2","claim":"Craig R. Jalbert was appointed as Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary at Viracta Therapeutics, Inc..","evidence_excerpt":"the Board appointed Craig R. Jalbert, age 63, as the Company's Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary, and sole member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"8bc7b1dd01","claim":"Darrel P. Cohen departed as Chief Medical Officer at Viracta Therapeutics, Inc..","evidence_excerpt":"it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"a557ed93e1","claim":"Thomas E. Darcy resigned as Director at Viracta Therapeutics, Inc..","evidence_excerpt":"Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b50d972d6d","claim":"Mark Rothera resigned as Director at Viracta Therapeutics, Inc..","evidence_excerpt":"Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e535928a3b","claim":"Ivor Royston resigned as Director at Viracta Therapeutics, Inc..","evidence_excerpt":"Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f9017d67f0","claim":"Flavia Borellini resigned as Director at Viracta Therapeutics, Inc..","evidence_excerpt":"Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"200c625c7adfad3938e4bb6e5a0f5f938dd42844","claim":"Viracta Therapeutics, Inc. announced a restructuring with charges of approximately $0.1 million.","evidence_excerpt":"The Company expects to incur one-time charges and cash expenditures associated with the workforce reduction of approximately $0.1 million, primarily related to employee wages and severance payments, benefits and related termination costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017025014630/0000950170-25-014630-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.1 million"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}